55 results about "Ovulation times" patented technology

A contraceptive device for placement in a fallopian tube includes expanding distal and proximal anchor members and an expandable elongate member connecting the distal anchor member to the proximal anchor member. An expandable material is disposed on at least a portion of the contraceptive device, whereupon delivery of the contraceptive device, the expandable material expands to completely occlude the fallopian tube. The expandable material may contain a drug, therapeutic agent, or hormone which is released over time to occlude or otherwise prevent the passage of spermazoa through the fallopian tube, or prevent ovulation. The contraceptive device may be delivered non-operatively and provide complete sterilization within a period of days. The device and delivery method obviates the need for follow-up visits to confirm closure of the fallopian tubes.

The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.

This invention relates to a multi-phase combination preparation that contains at least 28 daily dosage units: with a first phase of at least 21 initial daily dosage units, containing a competitive progesterone antagonist in a dosage which inhibits ovulation during the first above-named phase; and a second phase of 5 to 28 daily dosage units, in which each dosage unit of this second phase contains a gestagen, as well as a corresponding package (contraceptive kit) that contains this combination preparation and a contraceptive method which uses the combination preparation above.

A method of diagnosing ovulation in a female mammal comprises measuring the pH of the ectocervix of the female mammal and comparing the pH measured of the ectocervix to a reference value.

A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.

The invention relates to a drug for treating polycystic ovarian syndrome. The drug is characterized by comprising an oral medicine and an enema medicine, wherein the oral medicine comprises 15 g of common curculigo rhizome, 10 g of epimedium, 15 g of common cnidium fruit, 15 g of medicinal morinda root, 15 g of dodder, 15 g of glossy privet fruit, 15 g of medlar, 10 g of prepared rhizome of rehmannia, 15 g of angelica, 15 g of szechwan lovage rhizome, 15 g of salvia miltiorrhiza, 15 g of dangshen, 15 g of stir-fried ovate atractylodes root, 15 g of tuckahoe, 30 g of common yam rhizome, 15 g of pinellia, 12 g of seasoned orange peel, and 15 g of officinal magnolia bark, and the enema medicine comprises 15 g of peach seed, 10 g of safflower, 15 g of common burreed tuber, 12 g of cassiabarktree twig, 15 g of trumpetweed, 15 g of speranskia tuberculata, 15 g of common selfheal spike, 15 g of Chinese honeylocust spine, 15 g of szechwan lovage rhizome, 15 g of seaweed, and 15 g of kelp. According to the present invention, treatment philosophy of combination of the oral medicine and the enema medicine is adopted, and blood circulation activating, blood stasis dissipating, swelling subsiding, and stagnation eliminating are adopted to reduce intumescent ovary and thin ovarian follicle, such that ovulation easily occurs.

A method for detecting the onset of ovulation in a female mammal is provided. The method comprises contacting mouth air of the female mammal with an arylmethane test chromogen in an amount effective to undergo a rapid and detectable color change in the presence of one or more volatile sulfur compounds. The color of the test chromogen is compared to a control color that corresponds to a pre-ovulatory sulfur content. The difference in color between the test chromogen and the control color is correlated to the onset of ovulation.

The present invention provides a therapeutic agent for treating polycystic ovary syndrome (PCOS), which exhibits few, if any, side effects, is effective at inducing ovulation, and is safely available for not only females who desire to bear children, but also for unmarried or young females. A therapeutic agent for polycystic ovary syndrome (PCOS) in which an extract of mushrooms is contained as the active ingredient thereof is used.

An electronic system for determining a time of the temperature nadir of a female human during the menstrual cycle comprises a wearable device (1) that includes a first sensor system (104), configured to determine a temperature of the female human, and a second sensor system (101, 102, 103), configured to determine one or more further physiological parameters of the female human. The electronic system further comprises a processor (13, 30, 40), configured to determine a detected starting point of the fertility phase of the female human, using the one or more further physiological parameters of the female human. The processor (13, 30, 40) is further configured to detect the temperature nadir as a temporary decrease in the temperature, using the detected starting point of the fertility phase of the female human. The time of the temperature nadir is used as an indicator of the time of ovulation and peak oestrogen level.

In a new pharmaceutical combination, the herb, Vitex agnus-castus (chasteberry), enhances hormone balance by increasing progesterone release and, therefore, ovulation frequency. The antioxidants, green tea, vitamin E, and selenium, improve overall reproductive health. L-arginine, an amino acid, stimulates the reproductive organs by improving circulation. Folic acid, vitamins B6 and B12, iron, zinc and magnesium help promote womens' fertility. Sperms are highly susceptible to free radical or oxidative damage from environmental toxicants and natural aging. Vitamins C and E, coenzyme Q10 and selenium are all potent antioxidants that help improve sperm counts and quality. Ferulic acid, an antioxidant found in Dong quai, also improves sperm quality. Zinc and B vitamins (B6, B12 and folate) are critical nutrients in male reproductive systems for hormone metabolism, sperm formation and motility. The amino acid, L-carnitine, promotes formation of healthy sperm.

The invention discloses a dendrobium candidum medicine for treating female infertility. The effective components of the dendrobium candidum medicine for treating the female infertility are prepared from the following raw materials by weight: 15-30g of dendrobium candidum, 10-15g of blood ganoderma, 10-20g of mulberry, 8-12g of polygonatum, 8-15g of Chinese wolfberry, 6-10g of motherwort, 6-12g of cyperus rotundus, 8-12g of liquorice, 8-12g of lycopus lucidus, 6-10g of safflower, 4-8g of folium artemisiae argyi, 4-8g of angelica, 4-8g of ginseng, 6-12g of cinnamon, 4-10g of limonium sinense and 4-8g of glossy privet fruit. Pills or capsules of the dendrobium candidum medicine are prepared by uniformly mixing the 16 Chinese herbs, grinding, sieving, pilling or encapsulating. The dendrobium candidum medicine can improve ovarian development, adjust female menstruation and the ovulation state, promote uterine development and improve the pregnancy condition, has a good therapeutic effect in clinical trials, takes the Chinese herbs as the raw materials, and is small in toxic and side effects, easy to prepare and popularize.

The present invention relates to a method and composition for use in treating a condition that benefits from the reduction of hepatic and / or visceral fat, such as polycystic ovary syndrome in adolescent girls or women of childbearing age, involving the use of spironolactone, pioglitazone and metformin.

The invention discloses a traditional Chinese medicine composition for treating hypomenorrhea. The traditional Chinese medicine composition consists of the following traditional Chinese medicine raw materials in parts by weight: 15 parts of cuscuta chinensis, 15 parts of barbary wolfberry fruit, 9 parts of mistletoe, 15 parts of himalayan teasel root, 12 parts of eucommia ulmoides, 15 parts of prepared fleece flower root, 12 parts of Chinese yam, 10 parts of codonopsis pilosula, 15 parts of semen coicis, 12 parts of rehmannia glutinosa, 12 parts of Chinese angelica, 9 parts of white paeony root, 12 parts of rhizoma cyperi, 12 parts of radix bupleuri, 9 parts of red paeony root, 20 parts of salvia miltiorrhiza, 15 parts of caulis spatholobi, 15 parts of achyranthes bidentata amd 6 parts of prepared liquorice root. The traditional Chinese medicine has the basic effects of tonifying the kidney and replenishing essence and has the effects of relieving liver for smooth Qi and promoting blood circulation to remove blood stasis; and modern pharmacological studies prove that the reproductive axis of hypothalamus-hypophysis-ovary-uterus can be adjusted through the medicine, ovulation and luteal development are promoted, the ovary microcirculation is improved, and the medicine has the obvious effect of treating hypomenorrhea.

The invention is a hand held ovulation predictor device, which includes an ovulation predictor device body, an optical subassembly containing one or more aspheric lenses, an electronics assembly, a battery compartment, a light source and, optionally, a cover. The preferred embodiment of this invention is one in which the one or more lenses are aspheric.

The invention discloses a method for preparing an inhibin genetic engineering regulation antigen, which comprises the following steps: cloning an inhibin encoding gene; making use of the inhibin encoding gene to prepare an inhibin recombinant fusion protein; and making use of the inhibin recombinant fusion protein to prepare the inhibin genetic engineering regulation antigen. The method for preparing the inhibin genetic engineering regulation antigen has the advantages of simplicity, high purity, good immunogenicity, low price and the like; the inhibin genetic engineering regulation antigen prepared by the method does not have toxicity, pathogenicity and drug residue, is harmless to human and animals, has no adverse effect on consumers, can improve the ovulation rate and the litter size, improve utilization ratio of a superovulation embryo, promote the sexual maturation so as to improve the reproduction and the like.

A method of using a medical food to increase human fertility. This medical food consists of transfer factor, lactic acid generating bacteria, and glucans in appropriate combinations. The medical food, administered correctly, reduces cortisol levels. Progesterone increases as cortisol decreases, and progesterone is needed to support pregnancy and ovulation. Dosage amounts are adjusted for client weight. Typically, consumption of the medical food begins several days before planned conception.

The present invention relates to methods of increasing likelihood of conception, treatment of low fecundity and / or providing menstrual cycle control without suppressing ovulation in a female comprising administering an effective dose of at least one estrogen and at least one progestin within a treatment period of at least 21 days to 35 days or multiple periods thereof. Furthermore, the invention relates to the combination of at least one estrogen and at least one progestin for the preparation of a medicament to be used in the abovementioned indications. A pharmaceutical kit, according to the invention, comprises 21 to 35 dosage units or a multiple of 21 to 35 dosage units, wherein a first section comprises at most 21 dosage units of at least one estrogen; and a second section comprises from 2 to 34 dosage units of at least one estrogen and from 2 to 34 dosage units of at least one progestin or comprises from 2 to 34 dosage units of at least one estrogen and at least one progestin provided that in each dosage unit containing a progestin or a progestin and an estrogen the progestin is in a non-ovulation inhibiting amount; and and optionally a third section comprises at most 10 dosages of a pharmaceutically acceptable placebo or a blank.

The invention relates to a preparation with effect of assisting pregnancy for treating sterility due to ovulatory dysfunction, and a preparation method thereof. The preparation is prepared from the following materials (by weight part): Herba Epimedii (processed) 110-240, Cuscuta chinensis seed 160-240, Colla cornus cervi 25-45, Angelica sinensis 80-125, Astragalus membranaceus 135-265, Paeonia lactiflora 75-155, Rehmannia glutinosa 60-150, Fructus Amomi 50-145, Scutellaria baicalensis 50-120, Cyperus rotundus (processed) 100-220, and Rhizoma Et Radix Notopterygii 60-110. The effective ingredients of the raw materials in the preparation are extracted by decoction, and activities thereof are remained, so as to remarkably improve the dissolution rate, promote absorption of the effective ingredients, and improve bioavailability. In addition, the preparation is a pure Chinese medicinal preparation, thereby resulting in good safety and no toxic or side effects after long-term administration.

A method of treating a human female with an androgen and a gonadotropin to improve at least one of the human female's infertility, reproductive outcomes and oocyte yield is disclosed. The method may include treating the female with an androgen and a gonadotropin in combination. The androgen may be administered for more than six weeks and the gonadotropin may be administered in a regular low dosage over a period of time longer than two weeks. The method may include inducing ovulation in the female by administering gonadotropins to stimulate ovulation and / or induce ovulation. The method may include multiple additional inductions of ovulation, each within 120 days of the previous induction of ovulation.

Novel phenothiazine derivatives and their use in the treatment of diabetes mellitus (type I and type II), and as an ovulation inhibitor (contraceptive), cancer chemotherapeutic and / or prophylactic agent, anti-obesity drug (body weight regulator), and immunostimulant.

Disclosed herein is an ovulation detection apparatus. The ovulation detection apparatus includes a skin resistance measuring means for measuring the resistance value of the skin of fingers, a body temperature measuring means for measuring the temperature value of a tongue, and a potential difference measuring means for measuring the potential difference value of the mucus of a mouth. In the ovulation detection apparatus, a control means doubly determines whether an examinee is ovulating by selecting reference body temperature and potential difference values according to a measured skin resistance value and comparing measured body temperature and potential difference values with the reference body temperature and potential difference values, respectively. The ovulation detection apparatus further includes an output means for outputting the determination result of the control means so as to allow a user to recognize it, a power source for supplying electricity to the means, and an on-off switch for selectively turning on and off electricity supplied from the power source.

This invention relates to methods to predict and monitor ovulation and fertility in female mammals by measuring the level of free salivary estradiol. Such information may be used to identify the appropriate timing for egg retrieval prior to in vitro fertilization (IVF), insemination procedures, natural or otherwise, and the timing for transfer of embryos. The ability to monitor salivary estradiol levels throughout the estrous cycle, with the optional application of an algorithm, will aid in identifying the peak time of fertility.

The present invention is directed to the identification of a novel domain of functional significance on the GDF-9 and GDF-9B molecules and to peptides and antibodies which interact with the domain to modulate the biological activity of these molecules to alter mammalian ovarian function and ovulation rate.

The invention discloses a traditional Chinese medicine for assistant treatment of fallopian tube obstructive infertility and a preparation method thereof. The traditional Chinese medicine is prepared from dodder, dipsacus root, herba taxilli, eucommia, prepared rehmannia, white peony root, ligusticum wallichii, peach kernel, salviae miltiorrhizae and Chinese angelica by a traditional Chinese medicinal process. The traditional Chinese medicine is scientific and reasonable in process and easy to operate, can improve the internal environment of a body to enable the body to be balanced in yin and yang and invigorated in vital energy and blood, and leads coordination of organ functions, so that the ovulation function can be recovered. The traditional Chinese medicine has an effect of assistant treatment to patients after tubal repatancy and plastic surgery, the postoperative recanalization rate and pregnancy rate can be improved, and an economical and effective method for treating fallopian tube obstructive infertility is provided to patients.

The invention provides methods and kits for monitoring the status of women's health, including HRT monitoring and determination or diagnosis of ovulation, contraception, pregnancy, menopause, polycystic ovarian disease, and female sexual dysfunction. The method comprises the steps of: (a) collecting a tear fluid from a female human; (b) determining the tear concentration of at least one hormone of relevance to female fertility, sexual differentiation or sexual dysfunction in a female human, wherein the tear concentration is diagnostics of the status of women's health.

The invention discloses a special visual inseminating syringe for equus animals and an artificial insemination method thereof. The syringe comprises an outer barrel, an inseminating tube, an endoscopeand an inflation device, wherein the outer barrel is internally provided with an endoscope mounting channel and a working channel for inserting the inseminating tube; the inseminating tube comprisesan outer-layer hose and a rigid inner core; a sperm outlet through hole is formed in the front end of the outer-layer hose; the rigid inner core is arranged in the outer-layer hose and is in sliding match with the outer-layer hose; the rigid inner core can be pulled out from the tail part of the outer-layer hose; an air channel of the inflation device is communicated with a working channel in theouter barrel. The inseminating syringe disclosed by the invention is used for carrying out artificial insemination and an arm does not need to enter a genital tract of an estrous female animal, so that the simulation to vaginas and uterine cervixes is remarkably reduced; urination of the inseminated female animal is not caused, and the ovulation of the female animal and the quality of c are also not influenced, so that the probability of combining sperms and the ova and the quality of the ova are increased and the cycle conception rate of the artificial insemination is improved.